top of page
Diurnal Group
1 April 2022
The SMC impact and revised outlook
A challenging start to 2022, but potential remains
14 February 2022
The opportunity in AI and TRT
Driving the franchise
14 December 2021
2022 Outlook
2021 Execution, 2022 Delivery
30 September 2021
FY 2021 Results and Outlook
Smart Delivery
9 August 2021
Efmody launch and outlook
Commercialisation the key for now
28 July 2021
Trading update for FY 20/21
Momentum building
3 June 2021
Efmody EU approval
Globalisation of the adrenal franchise
26 March 2021
Efmody (Chronocort) CHMP opinion
Back on Track
bottom of page